Astena Holdings Co., Ltd. Logo

Astena Holdings Co., Ltd.

Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.

8095 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町四丁目8番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Astena Holdings Co., Ltd., formerly Iwaki & Co Ltd, is a diversified holding company established on June 1, 2021, following the transition of the IWAKI Group. The company operates through several core business segments: Fine Chemicals, Health & Beauty Care (HBC), Medical, Food, and Industrial Chemicals. Astena Holdings develops, manufactures, and wholesales a broad portfolio of products, including pharmaceuticals, medical devices, cosmetic ingredients, functional food ingredients, and specialty chemicals. A key subsidiary, Meltex, is a leading provider of surface finishing chemicals used in various industries, including semiconductors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-18 08:03
M&A Activity
臨時報告書
Japanese 28.5 KB
2025-07-11 08:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-07-11 08:06
Interim Report
半期報告書-第86期(2024/12/01-2025/11/30)
Japanese 245.6 KB
2025-03-06 07:04
Post-Annual General Meeting Information
臨時報告書
Japanese 23.9 KB
2025-02-27 08:04
Regulatory News Service
内部統制報告書-第85期(2023/12/01-2024/11/30)
Japanese 22.1 KB
2025-02-27 08:03
Regulatory News Service
確認書
Japanese 8.2 KB
2025-02-27 08:02
Annual Report
有価証券報告書-第85期(2023/12/01-2024/11/30)
Japanese 1.4 MB
2025-01-30 07:05
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-07-12 08:06
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-07-12 08:05
Quarterly Report
四半期報告書-第85期第2四半期(2024/03/01-2024/05/31)
Japanese 249.6 KB
2024-04-12 08:13
Quarterly Report
確認書
Japanese 8.1 KB
2024-04-12 08:10
Quarterly Report
四半期報告書-第85期第1四半期(2023/12/01-2024/02/29)
Japanese 203.6 KB
2024-03-04 08:10
Regulatory News Service
臨時報告書
Japanese 25.0 KB
2024-02-28 08:35
Registration Form
確認書
Japanese 8.1 KB
2024-02-28 08:34
Governance Information
内部統制報告書-第84期(2022/12/01-2023/11/30)
Japanese 22.1 KB

Automate Your Workflow. Get a real-time feed of all Astena Holdings Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Astena Holdings Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea 017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220

Talk to a Data Expert

Have a question? We'll get back to you promptly.